Merck Secures $700M Investment from Blackstone to Fast-Track Next-Gen Cancer Drug
Merck announced a major funding agreement to boost its cancer drug development. The company will receive $700 million from Blackstone Life Sciences. This money will help fund the development of an experimental cancer therapy, sacituzumab tirumotecan (sac-TMT). The new drug is an antibody-drug conjugate (ADC). ADCs are special treatments. They deliver anti-cancer drugs directly to…